Materials for archers (ASX:AXE) announced progress in the development of graphene field-effect transistor (gFET) sensors for its Biochip technology, a platform aimed at revolutionizing chronic kidney disease diagnostics. Recent testing conducted by the company has improved operational stability and design, moving us closer to the feasibility stages of product development.
The Biochip’s gFET sensors are designed to measure potassium levels in the blood, a critical factor in the diagnosis and management of chronic kidney disease. Archer’s team has developed an electrical conditioning procedure that significantly increases the repeatability of the measurement, up to tenfold. This improvement reduces variability in voltage responses, a key parameter for obtaining accurate potassium readings. Benchmarking experiments conducted with RMIT University further validated the performance of the gFET compared to other biosensors.
Greg English, Executive Chairman of Archer, commented: “The Archer team has made some important progress in bringing the biochip to the feasibility stage and improving the accuracy of blood potassium testing for chronic kidney disease. These developments are fundamental to the ultimate goal of the project.” Biochip, which will bring chronic kidney disease testing to the home and therefore improve patient outcomes through better diagnoses and treatments.”
Archer’s efforts also include the creation of datasets to evaluate sensor stability and batch-to-batch reproducibility by foundry partners. These data sets inform the feasibility program and will guide continued improvements in sensor design and manufacturing to meet clinical standards.